alendronate and Bone Cancer studies

alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.

Research Excerpts

Excerpt	Relevance	Reference
"To considerably enhance treatment efficacy for bone metastatic breast cancer via dual bone/tumor-targeted chemotherapy, a nanoparticle-based delivery system comprising poly(lactic-co-glycolic acid) (PLGA) as the hydrophobic core coated with alendronate-modified d-α-tocopheryl polyethylene glycol succinate (ALN-TPGS) and folic acid-conjugated TPGS (FA-TPGS) was developed as a vehicle for paclitaxel (PTX) in this work."	7.96	Alendronate/folic acid-decorated polymeric nanoparticles for hierarchically targetable chemotherapy against bone metastatic breast cancer. ( Chen, HH; Chen, SH; Chiang, WH; Chiu, HC; Chuang, CL; Liu, TI, 2020)
"The aim of this paper was to assess the effects of zoledronate (ZOL) and alendronate (FOS) on apoptotic behavior and gene expression of pro- and inflammatory cytokines of three cell types (human osteoblasts, human gingival fibroblasts and human osteogenic sarcoma cell lines) during a period of 4 weeks."	7.88	Cytotoxic and inflammatory effects of alendronate and zolendronate on human osteoblasts, gingival fibroblasts and osteosarcoma cells. ( Açil, Y; Arndt, ML; Ayna, M; Gülses, A; Naujokat, H; Wieker, H; Wiltfang, J, 2018)
" Here we demonstrate the divergent roles of ATP and adenosine released by bone osteocytes on breast cancers."	7.81	Differential impact of adenosine nucleotides released by osteocytes on breast cancer growth and bone metastasis. ( Ellies, LG; Gao, X; Jiang, JX; Riquelme, MA; Sun, LZ; Zhou, JZ, 2015)
"Paclitaxel (PTX) and alendronate (ALN) are effective drugs used for the treatment of breast cancer bone metastases."	7.79	Poly(ethylene glycol)-paclitaxel-alendronate self-assembled micelles for the targeted treatment of breast cancer bone metastases. ( Barshack, I; Benayoun, L; Clementi, C; Eldar-Boock, A; Miller, K; Pasut, G; Polyak, D; Satchi-Fainaro, R; Shaked, Y, 2013)
"The effect of different concentrations of alendronate on cell proliferation, migration, apoptosis and cytoskeleton reorganization as well as on the regulation of intracellular protein expression were analyzed for the high-grade chondrosarcoma cell line CS-1."	7.75	Alendronate inhibits growth of high-grade chondrosarcoma cells. ( Horiuchi, K; Hornicek, FJ; Morii, T; Morioka, H; Susa, M; Toyama, Y; Weissbach, L; Yabe, H, 2009)
"Our findings suggest that alendronate may reduce MMP-2 secretion at the transcriptional and translational levels, and inhibit the invasion of chondrosarcoma cell."	7.74	Alendronate inhibits cell invasion and MMP-2 secretion in human chondrosarcoma cell line. ( Chou, MC; Fong, YC; Hsu, CJ; Hsu, HC; Hsu, SF; Lai, TJ; Lee, MC; Li, TM; Lin, JG; Yang, SF, 2007)
" In the present report we address, in a single in vivo mouse model, the effects the bisphosphonate alendronate has on bone cancer pain, bone remodeling and tumor growth and necrosis."	7.72	Bone cancer pain: the effects of the bisphosphonate alendronate on pain, skeletal remodeling, tumor growth and tumor necrosis. ( De Felipe, C; Ghilardi, JR; Kuskowski, MA; Luger, NM; Mach, DB; Mantyh, PW; Peters, CM; Röhrich, H; Sabino, MA; Schwei, MJ; Sevcik, MA, 2004)
"Alendronate, a bisphosphonate compound, lowers serum calcium in patients with cancer-associated hypercalcemia through its inhibitory effect on bone resorption and as a result symptoms associated with hypercalcemia improve."	7.70	Effects of alendronate on bone metastases and hypercalcemia after surgery for hepatocellular carcinoma. ( Kinoshita, T; Matsumoto, T; Miyake, H; Ohnishi, T; Takeda, E; Tashiro, S; Terashima, Y; Yogita, S, 2000)
"The bisphosphonate drug alendronate was used to suppress bone remodelling and tumour osteolysis as a palliative treatment for two dogs with osteosarcoma, one of the tibia and one of the maxilla."	7.70	Use of the bisphosphonate drug alendronate for palliative management of osteosarcoma in two dogs. ( Muir, P; Pead, MJ; Sturgeon, C; Tomlin, JL, 2000)
"Women, in either study, with recurrent breast cancer or who reported a history of breast cancer were excluded from analyses."	6.79	Effect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic acid. ( Barrett-Connor, E; Bauer, DC; Black, DM; Cauley, JA; Cummings, SR; Ensrud, KE; Hue, TF, 2014)
"Curcumin has a proven anticancer potential with known challenges for application as a pharmaceutical agent."	5.56	Bisphosphonate-functionalized micelles for targeted delivery of curcumin to metastatic bone cancer. ( Kamble, S; Müllner, M; Pelras, T; Rohanizadeh, R; Varamini, P, 2020)
"Curcumin (CUR) is a general ingredient of traditional Chinese medicine, which has potential antitumor effects."	5.51	Dual targeting curcumin loaded alendronate-hyaluronan- octadecanoic acid micelles for improving osteosarcoma therapy. ( Chen, D; He, H; Jiang, T; Shen, Y; Wang, W; Webster, TJ; Wen, J; Xi, Y; Xu, N; Xue, M; Ye, X; Yu, J; Yu, Y, 2019)
"Although the prognosis of patients with breast cancer continues to improve, breast cancer metastasis to bones remains high in incidence and challenging to manage."	5.51	Alendronate-Modified Polymeric Micelles for the Treatment of Breast Cancer Bone Metastasis. ( Bronich, TK; Cohen, SM; Hyun, MA; Liu, T; Romanova, S; Singh, RK; Wang, S; Zhang, C, 2019)
"Many cancers, such as human breast cancer and lung cancer, easily metastasize to bones, leading to the formation of secondary tumors in advanced stages."	5.48	In Vivo Evaluation of Reduction-Responsive Alendronate-Hyaluronan-Curcumin Polymer-Drug Conjugates for Targeted Therapy of Bone Metastatic Breast Cancer. ( Chen, D; Dong, X; Guo, C; Liu, W; Wang, B; Wang, K; Yu, Y, 2018)
"1 mg/kg twice weekly or weekly) and dosing along with taxol (10-50 mg/kg/day, twice weekly, or weekly) blocked the growth of PC-3 ML tumors in the bone marrow and soft tissues in a statistically significant manner and improved survival rates significantly (p < 0."	5.29	Effects of alendronate and taxol on PC-3 ML cell bone metastases in SCID mice. ( Stearns, ME; Wang, M, 1996)
"To considerably enhance treatment efficacy for bone metastatic breast cancer via dual bone/tumor-targeted chemotherapy, a nanoparticle-based delivery system comprising poly(lactic-co-glycolic acid) (PLGA) as the hydrophobic core coated with alendronate-modified d-α-tocopheryl polyethylene glycol succinate (ALN-TPGS) and folic acid-conjugated TPGS (FA-TPGS) was developed as a vehicle for paclitaxel (PTX) in this work."	3.96	Alendronate/folic acid-decorated polymeric nanoparticles for hierarchically targetable chemotherapy against bone metastatic breast cancer. ( Chen, HH; Chen, SH; Chiang, WH; Chiu, HC; Chuang, CL; Liu, TI, 2020)
"The aim of this paper was to assess the effects of zoledronate (ZOL) and alendronate (FOS) on apoptotic behavior and gene expression of pro- and inflammatory cytokines of three cell types (human osteoblasts, human gingival fibroblasts and human osteogenic sarcoma cell lines) during a period of 4 weeks."	3.88	Cytotoxic and inflammatory effects of alendronate and zolendronate on human osteoblasts, gingival fibroblasts and osteosarcoma cells. ( Açil, Y; Arndt, ML; Ayna, M; Gülses, A; Naujokat, H; Wieker, H; Wiltfang, J, 2018)
" Here we demonstrate the divergent roles of ATP and adenosine released by bone osteocytes on breast cancers."	3.81	Differential impact of adenosine nucleotides released by osteocytes on breast cancer growth and bone metastasis. ( Ellies, LG; Gao, X; Jiang, JX; Riquelme, MA; Sun, LZ; Zhou, JZ, 2015)
"Paclitaxel (PTX) and alendronate (ALN) are effective drugs used for the treatment of breast cancer bone metastases."	3.79	Poly(ethylene glycol)-paclitaxel-alendronate self-assembled micelles for the targeted treatment of breast cancer bone metastases. ( Barshack, I; Benayoun, L; Clementi, C; Eldar-Boock, A; Miller, K; Pasut, G; Polyak, D; Satchi-Fainaro, R; Shaked, Y, 2013)
" We have recently developed biodegradable, biocompatible nanoparticles (NP) made of a conjugate between poly (D,L-lactide-co-glycolic) acid and alendronate, suitable for systemic administration, and directly targeting the site of tumor-induced osteolysis."	3.76	Bone-targeted doxorubicin-loaded nanoparticles as a tool for the treatment of skeletal metastases. ( Angelucci, A; Avnet, S; Baldini, N; Capulli, M; Castelli, F; Cenni, E; Del Fattore, A; Fotia, C; Giunti, A; Granchi, D; Micieli, D; Pignatello, R; Rucci, N; Salerno, M; Teti, A; Zini, N, 2010)
"The effect of different concentrations of alendronate on cell proliferation, migration, apoptosis and cytoskeleton reorganization as well as on the regulation of intracellular protein expression were analyzed for the high-grade chondrosarcoma cell line CS-1."	3.75	Alendronate inhibits growth of high-grade chondrosarcoma cells. ( Horiuchi, K; Hornicek, FJ; Morii, T; Morioka, H; Susa, M; Toyama, Y; Weissbach, L; Yabe, H, 2009)
"Our findings suggest that alendronate may reduce MMP-2 secretion at the transcriptional and translational levels, and inhibit the invasion of chondrosarcoma cell."	3.74	Alendronate inhibits cell invasion and MMP-2 secretion in human chondrosarcoma cell line. ( Chou, MC; Fong, YC; Hsu, CJ; Hsu, HC; Hsu, SF; Lai, TJ; Lee, MC; Li, TM; Lin, JG; Yang, SF, 2007)
" In the present report we address, in a single in vivo mouse model, the effects the bisphosphonate alendronate has on bone cancer pain, bone remodeling and tumor growth and necrosis."	3.72	Bone cancer pain: the effects of the bisphosphonate alendronate on pain, skeletal remodeling, tumor growth and tumor necrosis. ( De Felipe, C; Ghilardi, JR; Kuskowski, MA; Luger, NM; Mach, DB; Mantyh, PW; Peters, CM; Röhrich, H; Sabino, MA; Schwei, MJ; Sevcik, MA, 2004)
"The bisphosphonate drug alendronate was used to suppress bone remodelling and tumour osteolysis as a palliative treatment for two dogs with osteosarcoma, one of the tibia and one of the maxilla."	3.70	Use of the bisphosphonate drug alendronate for palliative management of osteosarcoma in two dogs. ( Muir, P; Pead, MJ; Sturgeon, C; Tomlin, JL, 2000)
"Alendronate, a bisphosphonate compound, lowers serum calcium in patients with cancer-associated hypercalcemia through its inhibitory effect on bone resorption and as a result symptoms associated with hypercalcemia improve."	3.70	Effects of alendronate on bone metastases and hypercalcemia after surgery for hepatocellular carcinoma. ( Kinoshita, T; Matsumoto, T; Miyake, H; Ohnishi, T; Takeda, E; Tashiro, S; Terashima, Y; Yogita, S, 2000)
"To investigate the safety of rapid infusion of alendronate, we used alendronate therapy for 11 breast cancer patients with bone metastasis."	3.70	[A study of the safety of rapid infusion of alendronate]. ( Kokawa, Y; Oura, S; Sakurai, T; Tamaki, T; Umemura, T; Yoshimura, G, 1999)
"Women, in either study, with recurrent breast cancer or who reported a history of breast cancer were excluded from analyses."	2.79	Effect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic acid. ( Barrett-Connor, E; Bauer, DC; Black, DM; Cauley, JA; Cummings, SR; Ensrud, KE; Hue, TF, 2014)
"Ketoconazole (KT) has demonstrated activity in androgen independent prostate cancer (AIPC)."	2.71	A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases. ( Arlen, P; Chen, CC; Cox, MC; Cremers, S; Dahut, WL; Figg, WD; Gulley, J; Jones, E; Liewehr, DJ; Liu, Y; Parr, A; Steinberg, SM; Yang, X; Zhai, S, 2005)
"Treatment with zoledronic acid probably neither reduces nor increases the proportion of participants with pain response when compared to no treatment/placebo (risk ratio (RR) 1."	2.66	Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. ( Adams, A; Heidenreich, A; Jakob, T; Kuhr, K; Macherey, S; Monsef, I; Skoetz, N; Tesfamariam, YM, 2020)
"The degree of pain is highly variable and adults reports more pain than children."	2.48	Pathophysiology and medical treatment of pain in fibrous dysplasia of bone. ( Chapurlat, RD; Gensburger, D; Ghilardi, JR; Jimenez-Andrade, JM; Kelly, M; Mantyh, P, 2012)
"Sarcoidosis is a multisystem disease of unknown origin."	2.47	Rare localizations of bone sarcoidosis: two case reports and review of the literature. ( Bargagli, E; Bertelli, P; Gonnelli, S; Olivieri, C; Penza, F; Rottoli, P; Volterrani, L, 2011)
" The variety of bisphosphonates currently available to us provides a wide range of tolerability and dosing profiles thus necessitating a thorough comparison of the most recent oral and intravenous bisphosphonates to differentiate the clinical context in which they should be used."	2.43	Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease. ( Adachi, JD; Beattie, K; Bobba, RS; Kumbhare, D; Parkinson, B, 2006)
"Oral etidronate has been found to be ineffective in patients with multiple myeloma and prostate carcinoma bone metastases."	2.41	Oral bisphosphonates: A review of clinical use in patients with bone metastases. ( Berenson, J; Hortobagyi, G; Lipton, A; Major, PP, 2000)
"They are used in the treatment of Paget's disease of bone, hypercalcaemia and osteolytic bone disease of malignancy, primary and secondary hyperparathyroidism, and in osteoporosis."	2.41	Bisphosphonates: an overview with special reference to alendronate. ( Vasikaran, SD, 2001)
"Osteosarcoma is well-known for its high incidence in children and adolescents and long-term bone pain, which seriously reduces the life quality of patients."	1.91	Bone-Targeted Dual Functional Lipid-coated Drug Delivery System for Osteosarcoma Therapy. ( Jia, Y; Lan, X; Ma, X; Su, YX; Wang, J; Wang, Y; Wen, W; Zhang, M; Zhong, J, 2023)
"Curcumin has a proven anticancer potential with known challenges for application as a pharmaceutical agent."	1.56	Bisphosphonate-functionalized micelles for targeted delivery of curcumin to metastatic bone cancer. ( Kamble, S; Müllner, M; Pelras, T; Rohanizadeh, R; Varamini, P, 2020)
"Curcumin (CUR) is a general ingredient of traditional Chinese medicine, which has potential antitumor effects."	1.51	Dual targeting curcumin loaded alendronate-hyaluronan- octadecanoic acid micelles for improving osteosarcoma therapy. ( Chen, D; He, H; Jiang, T; Shen, Y; Wang, W; Webster, TJ; Wen, J; Xi, Y; Xu, N; Xue, M; Ye, X; Yu, J; Yu, Y, 2019)
"Although the prognosis of patients with breast cancer continues to improve, breast cancer metastasis to bones remains high in incidence and challenging to manage."	1.51	Alendronate-Modified Polymeric Micelles for the Treatment of Breast Cancer Bone Metastasis. ( Bronich, TK; Cohen, SM; Hyun, MA; Liu, T; Romanova, S; Singh, RK; Wang, S; Zhang, C, 2019)
"Many cancers, such as human breast cancer and lung cancer, easily metastasize to bones, leading to the formation of secondary tumors in advanced stages."	1.48	In Vivo Evaluation of Reduction-Responsive Alendronate-Hyaluronan-Curcumin Polymer-Drug Conjugates for Targeted Therapy of Bone Metastatic Breast Cancer. ( Chen, D; Dong, X; Guo, C; Liu, W; Wang, B; Wang, K; Yu, Y, 2018)
"A cell line-specific, dose-related cytotoxicity was observed for 5-FdU-ale in all cancer cell lines tested, which was significantly less toxic than 5-FdU alone when compared to the benign osteoblasts or stromal cells."	1.42	In vitro and in vivo toxicity of 5-FdU-alendronate, a novel cytotoxic bone-seeking duplex drug against bone metastasis. ( Busch, C; Noor, S; Schem, C; Schott, S; Tiwari, S; Tower, RJ; Vallet, S, 2015)
"The alendronate was successfully incorporated onto the porous magnetite microspheres in vacuum conditions."	1.40	Bisphosphonate release profiles from magnetite microspheres. ( Inoue, T; Kawashita, M; Matsubara, T; Matsumine, A; Miyazaki, T; Shirosaki, Y, 2014)
"Breast or prostate cancer patients were treated with zoledronate."	1.39	Bisphosphonate-related osteonecrosis of jaw (BRONJ) in Japanese population: a case series of 13 patients at our clinic. ( Fujimoto, Y; Muramatsu, K; Murayama, M; Nakata, E; Nomura, T; Ogane, S; Sekine, R; Shibahara, T; Shibui, T; Uchiyama, T; Watanabe, A; Yakushiji, T; Yamamoto, N, 2013)
"Bone neoplasms, such as osteosarcoma, exhibit a propensity for systemic metastases resulting in adverse clinical outcome."	1.37	Enhanced anti-tumor activity and safety profile of targeted nano-scaled HPMA copolymer-alendronate-TNP-470 conjugate in the treatment of bone malignances. ( Benayoun, L; Kopeček, J; Kopečková, P; Pan, H; Satchi-Fainaro, R; Segal, E; Shaked, Y, 2011)
"The indication for BP was prevention or treatment of osteoporosis in 11 cases and breast with bone metastases in one case."	1.36	[Jaw osteonecrosis induced by oral biphosphonates: 12 cases]. ( Barrier, A; Descroix, V; Goudot, P; Lescaille, G; Rigolet, A; Ruhin, B, 2010)
" Twelve patients who presented with exposed bone associated with bisphosphonates were reviewed to determine the type, dosage and duration of their bisphosphonate therapy, presenting findings, comorbidities and the event that incited the bone exposure."	1.34	Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma and breast cancer. ( Alati, C; Allegra, A; Alonci, A; Cicciù, M; De Ponte, FS; Musolino, C; Nastro, E; Oteri, G; Quartarone, E, 2007)
"Sixty-two (52."	1.33	Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. ( Broumand, V; Fortin, M; Marx, RE; Sawatari, Y, 2005)
"Here we report 29 cases of bone necrosis of the jaws in patients treated with pamidronate (Aredia), zoledronate (Zometa) and alendronate: 15 underwent surgical procedures and 14 occurred spontaneously."	1.33	Bone necrosis of the jaws associated with bisphosphonate treatment: a report of twenty-nine cases. ( Bonaninil, M; Corcione, L; Corradi, D; D'Aleo, P; Ferrari, S; Guidotti, R; Manfredi, M; Meleti, M; Merigo, E; Poli, T; Ripasarti, A; Sesenna, E; Vescovi, P; Zanzucchi, E, 2006)
"Bone cancer was produced by intratibial inoculation of Walker carcinosarcoma cells, and a model of augmented bone resorption was produced by vitamin D(3) treatment of rats that had undergone thyroidparathyroidectomy."	1.31	Pharmacokinetic and pharmacodynamic evaluation of intermittent versus continuous alendronate administration in rats. ( Golomb, G; Hoffman, A; Stepensky, D, 2002)
"Alendronate pretreatment also inhibited migration, which was partially reversed by geranylgeraniol and trans-trans-farnesol."	1.31	Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway. ( Härkönen, PL; Lakkakorpi, PT; Väänänen, HK; Virtanen, SS, 2002)
"Alendronate failed to inhibit MMP-2 activity directly, but instead appeared to block cellular secretion of MMP-2."	1.30	Alendronate blocks TGF-beta1 stimulated collagen 1 degradation by human prostate PC-3 ML cells. ( Stearns, ME, 1998)
"Alendronate pretreatment of the SCID mice (0."	1.30	Alendronate blocks metalloproteinase secretion and bone collagen I release by PC-3 ML cells in SCID mice. ( Stearns, ME; Wang, M, 1998)
"To validate our hypothesis that a bisphosphonate (BP) having a nitrogen-containing heterocyclic ring on the side chain, and with no hydroxyl on the geminal carbon would possess increased activity, and better oral bioavailability due to enhanced solubility of its calcium complexes/salts and weaker Ca chelating properties."	1.30	Synthesis and preclinical pharmacology of 2-(2-aminopyrimidinio) ethylidene-1,1-bisphosphonic acid betaine (ISA-13-1)-a novel bisphosphonate. ( Alferiev, IS; Breuer, E; Cohen, H; Ezra, A; Golomb, G; Hägele, G; Hoffman, A; Mönkkönen, J; Ornoy, A; Patlas, N; Pinto, T; Sagi, H; Seibel, MJ; Solomon, V; Stepensky, D, 1999)
"1 mg/kg twice weekly or weekly) and dosing along with taxol (10-50 mg/kg/day, twice weekly, or weekly) blocked the growth of PC-3 ML tumors in the bone marrow and soft tissues in a statistically significant manner and improved survival rates significantly (p < 0."	1.29	Effects of alendronate and taxol on PC-3 ML cell bone metastases in SCID mice. ( Stearns, ME; Wang, M, 1996)

Research

Studies (89)

Authors

Clinical Trials (11)

Trial Overview

Trial Outcomes

Overall Survival

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (1.12)	18.7374
1990's	12 (13.48)	18.2507
2000's	24 (26.97)	29.6817
2010's	41 (46.07)	24.3611
2020's	11 (12.36)	2.80

Authors	Studies
Xue, X	1
Yu, J	2
Lu, F	1
Jiang, H	1
Wang, X	1
Wen, W	4
Guo, P	1
Xue, HY	1
Lun Wong, H	1
Liu, Y	3
Jiang, Z	1
Tong, S	1
Sun, Y	1
Zhang, Y	2
Zhang, J	1
Zhao, D	1
Su, Y	1
Ding, J	1
Chen, X	1
Zhong, J	3
Wang, J	3
Zhang, M	3
Jia, Y	3
Ma, X	3
Su, YX	3
Wang, Y	4
Lan, X	3
Damasco, JA	1
Yu, G	1
Kumar, A	1
Perez, J	1
Lirag, RCM	1
Whitley, EM	1
Lin, SH	1
Melancon, MP	1
Xi, Y	1
Jiang, T	1
Yu, Y	2
Xue, M	1
Xu, N	1
Wen, J	1
Wang, W	1
He, H	1
Shen, Y	2
Chen, D	2
Ye, X	1
Webster, TJ	1
Ravanbakhsh, M	1
Labbaf, S	1
Karimzadeh, F	1
Pinna, A	1
Houreh, AB	1
Nasr-Esfahani, MH	1
Quiñones Vélez, G	1
Carmona-Sarabia, L	1
Rodríguez-Silva, WA	1
Rivera Raíces, AA	1
Feliciano Cruz, L	1
Hu, T	1
Peterson, E	1
López-Mejías, V	1
Chen, SH	1
Liu, TI	1
Chuang, CL	1
Chen, HH	1
Chiang, WH	1
Chiu, HC	1
Bai, SB	1
Cheng, Y	2
Liu, DZ	1
Ji, QF	1
Liu, M	1
Zhang, BL	1
Mei, QB	2
Zhou, SY	2
Kamble, S	1
Varamini, P	1
Müllner, M	1
Pelras, T	1
Rohanizadeh, R	1
Wu, H	1
Luo, Y	1
Xu, D	1
Ke, X	1
Ci, T	1
Jakob, T	1
Tesfamariam, YM	1
Macherey, S	1
Kuhr, K	1
Adams, A	1
Monsef, I	1
Heidenreich, A	1
Skoetz, N	1
He, Y	1
Huang, Y	2
Huang, Z	1
Jiang, Y	1
Sun, X	1
Chu, W	2
Zhao, C	2
Açil, Y	1
Arndt, ML	1
Gülses, A	1
Wieker, H	1
Naujokat, H	1
Ayna, M	1
Wiltfang, J	1
Wang, K	1
Guo, C	2
Dong, X	1
Wang, B	1
Liu, W	1
Huang, Q	1
He, X	1
Chen, H	1
Zou, Y	1
Li, Y	2
Lin, K	1
Cai, X	1
Xiao, J	1
Zhang, Q	1
Zhu, J	1
Huo, Q	1
Xu, M	1
Yang, F	1
Shi, H	1
Niu, Y	1
Feng, S	1
Wu, ZX	1
Zhao, Z	1
Liu, J	2
Sun, K	1
Wang, H	1
Wu, Z	1
Liu, T	1
Romanova, S	1
Wang, S	1
Hyun, MA	1
Zhang, C	1
Cohen, SM	1
Singh, RK	1
Bronich, TK	1
Chaurand-Lara, J	1
Pacheco-Ruiz, L	1
Trejo-Campos, JL	1
Facio-Umaña, JA	1
Mora-Pérez, J	1
Miller, K	4
Clementi, C	2
Polyak, D	2
Eldar-Boock, A	2
Benayoun, L	3
Barshack, I	1
Shaked, Y	3
Pasut, G	2
Satchi-Fainaro, R	5
Nomura, T	1
Shibahara, T	1
Uchiyama, T	1
Yamamoto, N	1
Shibui, T	1
Yakushiji, T	1
Watanabe, A	1
Muramatsu, K	1
Ogane, S	1
Murayama, M	1
Sekine, R	1
Nakata, E	1
Fujimoto, Y	1
Morton, SW	1
Shah, NJ	1
Quadir, MA	1
Deng, ZJ	1
Poon, Z	1
Hammond, PT	1
Borm, JM	1
Moser, S	1
Locher, M	1
Damerau, G	1
Stadlinger, B	1
Grätz, KW	1
Jacobsen, C	1
Zhou, JZ	1
Riquelme, MA	1
Gao, X	1
Ellies, LG	1
Sun, LZ	1
Jiang, JX	1
Miyazaki, T	1
Inoue, T	1
Shirosaki, Y	1
Kawashita, M	1
Matsubara, T	1
Matsumine, A	1
Swami, A	1
Reagan, MR	1
Basto, P	1
Mishima, Y	1
Kamaly, N	1
Glavey, S	1
Zhang, S	1
Moschetta, M	1
Seevaratnam, D	1
Memarzadeh, M	1
Wu, J	1
Manier, S	1
Shi, J	1
Bertrand, N	1
Lu, ZN	1
Nagano, K	1
Baron, R	1
Sacco, A	1
Roccaro, AM	1
Farokhzad, OC	1
Ghobrial, IM	1
Hue, TF	1
Cummings, SR	1
Cauley, JA	1
Bauer, DC	1
Ensrud, KE	1
Barrett-Connor, E	1
Black, DM	1
Schott, S	2
Vallet, S	1
Tower, RJ	2
Noor, S	1
Tiwari, S	2
Schem, C	2
Busch, C	1
Ye, WL	1
Zhao, YP	1
Li, HQ	1
Na, R	1
Li, F	1
Zhao, MG	1
Liu, P	1
Sun, L	1
Zhou, DS	1
Zhang, P	1
Wang, YH	1
Li, D	1
Li, QH	1
Feng, RJ	1
Veszelyné Kotán, E	2
Mészaros, Á	2
Kneissl, P	1
Rambow, AC	1
Campbell, GM	1
Desel, C	1
Damm, T	1
Heilmann, T	1
Fuchs, S	1
Zuhayra, M	1
Trauzold, A	1
Glüer, CC	1
Nguyen, TD	1
Pitchaimani, A	1
Aryal, S	1
Yang, C	1
Liao, Y	1
Zhang, X	1
Yan, M	1
Cui, S	1
Wong, YK	1
Cheng, JC	1
Erez, R	1
Segal, E	3
Shabat, D	1
Susa, M	1
Morii, T	1
Yabe, H	1
Horiuchi, K	1
Toyama, Y	1
Weissbach, L	1
Hornicek, FJ	1
Morioka, H	1
Bargagli, E	1
Olivieri, C	1
Penza, F	1
Bertelli, P	1
Gonnelli, S	1
Volterrani, L	1
Rottoli, P	1
Torres Martin de Rosales, R	1
Finucane, C	1
Foster, J	1
Mather, SJ	1
Blower, PJ	1
Migliorati, CA	1
Mattos, K	1
Palazzolo, MJ	1
Salerno, M	2
Cenni, E	2
Fotia, C	2
Avnet, S	2
Granchi, D	2
Castelli, F	2
Micieli, D	2
Pignatello, R	2
Capulli, M	1
Rucci, N	1
Angelucci, A	1
Del Fattore, A	1
Teti, A	1
Zini, N	1
Giunti, A	1
Baldini, N	2
Barrier, A	1
Lescaille, G	1
Rigolet, A	1
Descroix, V	1
Goudot, P	1
Ruhin, B	1
Pan, H	1
Kopečková, P	1
Kopeček, J	1
Mero, A	1
Yoshitani, K	1
Kido, A	1
Honoki, K	1
Akahane, M	1
Fujii, H	1
Tanaka, Y	1
Sarpietro, MG	1
Bogado, CE	1
Boailchuk, JA	1
Zanchetta, MB	1
Massari, FE	1
Zanchetta, JR	1
Chapurlat, RD	1
Gensburger, D	1
Jimenez-Andrade, JM	1
Ghilardi, JR	2
Kelly, M	1
Mantyh, P	1
Thamake, SI	1
Raut, SL	1
Gryczynski, Z	1
Ranjan, AP	1
Vishwanatha, JK	1
Weinreich, J	1
Schott, TC	1
Königsrainer, I	1
Küper, M	1
Königsrainer, A	1
Schott, H	1
Carter, CJ	1
Ward, WG	1
Cheng, YY	1
Huang, L	1
Lee, KM	1
Xu, JK	1
Zheng, MH	1
Kumta, SM	1
Sevcik, MA	1
Luger, NM	1
Mach, DB	1
Sabino, MA	1
Peters, CM	1
Schwei, MJ	1
Röhrich, H	1
De Felipe, C	1
Kuskowski, MA	1
Mantyh, PW	1
Figg, WD	2
Arlen, P	1
Gulley, J	1
Steinberg, SM	1
Liewehr, DJ	1
Cox, MC	1
Zhai, S	1
Cremers, S	1
Parr, A	1
Yang, X	1
Chen, CC	1
Jones, E	1
Dahut, WL	1
Marx, RE	1
Sawatari, Y	1
Fortin, M	1
Broumand, V	1
Bobba, RS	1
Beattie, K	1
Parkinson, B	1
Kumbhare, D	1
Adachi, JD	1
Nastro, E	1
Musolino, C	1
Allegra, A	1
Oteri, G	1
Cicciù, M	1
Alonci, A	1
Quartarone, E	1
Alati, C	1
De Ponte, FS	1
Merigo, E	1
Manfredi, M	1
Meleti, M	1
Guidotti, R	1
Ripasarti, A	1
Zanzucchi, E	1
D'Aleo, P	1
Corradi, D	1
Corcione, L	1
Sesenna, E	1
Ferrari, S	1
Poli, T	1
Bonaninil, M	1
Vescovi, P	1
Pritchard, KI	1
Lai, TJ	1
Hsu, SF	1
Li, TM	1
Hsu, HC	1
Lin, JG	1
Hsu, CJ	1
Chou, MC	1
Lee, MC	1
Yang, SF	1
Fong, YC	1
Malden, NJ	1
Pai, AY	1
Udvardy, E	1
Redl, P	1
Márton, I	1
Koyano, H	1
Schimizu, T	1
Shishiba, Y	1
Body, JJ	1
Coleman, RE	1
Piccart, M	1
Stearns, ME	3
Wang, M	2
Adami, S	1
Oura, S	3
Sakurai, T	3
Yoshimura, G	3
Tamaki, T	3
Umemura, T	3
Kokawa, Y	3
Cohen, H	1
Alferiev, IS	1
Mönkkönen, J	1
Seibel, MJ	1
Pinto, T	1
Ezra, A	1
Solomon, V	1
Stepensky, D	2
Sagi, H	1
Ornoy, A	1
Patlas, N	1
Hägele, G	1
Hoffman, A	2
Breuer, E	1
Golomb, G	2
Major, PP	1
Lipton, A	1
Berenson, J	1
Hortobagyi, G	1
Naito, Y	1
Tomlin, JL	1
Sturgeon, C	1
Pead, MJ	1
Muir, P	1
Ohnishi, T	1
Takeda, E	1
Yogita, S	1
Miyake, H	1
Kinoshita, T	1
Terashima, Y	1
Matsumoto, T	1
Tashiro, S	1
Arteaga de Murphy, C	1
Ferro-Flores, G	1
Pedraza-López, M	1
Meléndez-Alafort, L	1
Croft, BY	1
Ramírez, FM	1
Padilla, J	1
Carrasquillo, JA	1
Whatley, M	1
Dyer, V	1
Dahut, W	1
Rubin, MR	1
Livolsi, VA	1
Bandeira, F	1
Caldas, G	1
Bilezikian, JP	1
Vasikaran, SD	1
Virtanen, SS	1
Väänänen, HK	1
Härkönen, PL	1
Lakkakorpi, PT	1
Zysset, E	1
Ammann, P	1
Jenzer, A	1
Gertz, BJ	1
Portmann, L	1
Rizzoli, R	1
Jaquet-Müller, F	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Phase II Randomized Study of High-Dose Ketoconazole With or Without Alendronate Sodium in Patients With Androgen-Independent Metastastic Adenocarinoma of the Prostate[NCT00019695]	Phase 2	0 participants	Interventional	1999-03-31	Terminated
Atrasentan and Zometa for Men With Androgen Independent Prostate Cancer Metastatic to Bone: A Randomized Pilot Study[NCT00181558]	Phase 2	44 participants	Interventional	2001-12-31	Completed
A Randomized Double-Blind, Placebo-Controlled Phase III Study of Early Versus Standard Zoledronic Acid to Prevent Skeletal Related Events in Men With Prostate Cancer Metastatic to Bone[NCT00079001]	Phase 3	645 participants (Actual)	Interventional	2004-01-31	Completed
A Randomized, Open Label, Active Controlled Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous Bisphosphonates[NCT00104650]	Phase 2	111 participants (Actual)	Interventional	2005-01-31	Completed
Randomized Placebo-Controlled Trial of Mitoxantrone/Prednisone and Clodronate Versus Mitoxantrone/Prednisone Alone in Patients With Hormone Refractory Metastatic Prostate Cancer and Pain[NCT00003232]	Phase 3	227 participants (Actual)	Interventional	1997-11-24	Completed
A Phase III, Multicenter, Randomized, Controlled Study of Maximum Androgen Blockade With vs. Without Zoledronic Acid in Prostatic Cancer Patients With Metastatic Bone Disease[NCT00685646]	Phase 3	227 participants (Actual)	Interventional	2008-05-31	Completed
A Randomised Phase II Feasibility Study of Docetaxel (Taxotere®) Plus Prednisolone vs. Docetaxel (Taxotere®) Plus Prednisolone Plus Zoledronic Acid (Zometa®) vs. Docetaxel (Taxotere®) Plus Prednisolone Plus Strontium-89 vs. Docetaxel (Taxotere®) Plus Pred[NCT00554918]	Phase 2	300 participants (Anticipated)	Interventional	2005-02-28	Completed
A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa®) in the Treatment of Bone Metastases in Men With Hormone-Refractory Prostate Cancer[NCT00321620]	Phase 3	1,904 participants (Actual)	Interventional	2006-04-01	Completed
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41[NCT00216060]	Phase 3	63 participants (Actual)	Interventional	2003-10-31	Terminated (stopped due to Terminated due to low accrual)
STAMPEDE: Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy: A Multi-Stage Multi-Arm Randomised Controlled Trial[NCT00268476]	Phase 2/Phase 3	11,992 participants (Actual)	Interventional	2005-07-08	Active, not recruiting
HORIZON-PFT: Pivotal Fracture Trial[NCT00049829]	Phase 3	7,700 participants	Interventional	2002-01-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Overall survival (OS) was defined as the time from randomization to death of any cause. Surviving patients were censored at the date of last follow-up. The median OS with 95% CI was estimated using the Kaplan Meier method. (NCT00079001)
Timeframe: Up to 10 years

Progression-free Survival

Intervention	months (Median)
Zoledronic Acid + Androgen Deprivation Therapy	37.9
Placebo + Androgen Deprivation Therapy	36.0

"Progression Free Survival (PFS) was defined as the time from registration until disease progression or death, whichever occurs first. The median PFS with 95% CI was estimated using the Kaplan-Meier method.~Progression is defined as one or more of the following: new bone metastases, biochemical progression of PSA, treatment with radiation therapy while on treatment." (NCT00079001)
Timeframe: Up to 10 years

Time to First Skeletal Related Event

Intervention	months (Median)
Zoledronic Acid + Androgen Deprivation Therapy	10.6
Placebo + Androgen Deprivation Therapy	9.2

Time to first skeletal related event (SRE) was defined as the time from randomization to first skeletal event. Skeletal events are defined as radiation to bone, clinical fracture, surgery to bone and spinal cord compression and death due to prostate cancer. The median with 95% CI was estimated using the Kaplan Meier method. (NCT00079001)
Timeframe: Up to 10 years

Duration of Maintaining uNTX (Corrected by Creatinine) < 50nmol/mmol

Intervention	months (Median)
Zoledronic Acid + Androgen Deprivation Therapy	31.9
Placebo + Androgen Deprivation Therapy	28.8

Time from the 1st occurrence of uNTx below 50 nmol BCE/mmol (corrected by creatinine) to the 1st occurrence of uNTx above 50 nmol BCE/mmol up to week 25. For participants who remained below 50 nmol BCE/mmol, the time is censored at the time of last evaluation of uNTx up to week 25. (NCT00104650)
Timeframe: Day 1, week 25

Hypercalcemia

Intervention	Participants (Number)
Bisphosphonate IV Q4W	25
Denosumab 180 mg Q12W	32
Denosumab 180 mg Q4W	35

Occurrence of hypercalcemia at grade 3 or 4 according to CTCAE v3 criteria (NCT00104650)
Timeframe: Day 1, week 25

Percent Change of Serum CTX From Baseline to Week 25

Intervention	Participants (Number)
Bisphosphonate IV Q4W	0
Denosumab 180 mg Q12W	0
Denosumab 180 mg Q4W	0

Percent change from baseline to week 25 in Type I serum C-Telopeptide (CTX), calculated using ((week 25 value - baseline value) / baseline value ) x 100. (NCT00104650)
Timeframe: Baseline, week 25

Percent Change of uNTx (Corrected by Creatinne) From Baseline to Week 25

Intervention	Percent change (Mean)
Bisphosphonate IV Q4W	-40.68
Denosumab 180 mg Q12W	-76.74
Denosumab 180 mg Q4W	-68.39

Percent change from baseline to week 25 urinary N-telopeptide (uNTX) calculated using ((week 25 value - baseline value) / baseline value ) x 100. (NCT00104650)
Timeframe: Baseline, week 25

Skeletal Related Events

Intervention	Percent change (Mean)
Bisphosphonate IV Q4W	-32.91
Denosumab 180 mg Q12W	-69.09
Denosumab 180 mg Q4W	-41.68

Skeletal Related Event (SRE), defined as >1 of the following: pathological bone fracture, spinal cord compression, surgery or radiation therapy to bone (including the use of radioisotopes). (NCT00104650)
Timeframe: Day 1, week 25

Time to First Skeletal Related Event

Intervention	Participants (Number)
Bisphosphonate IV Q4W	6
Denosumab 180 mg Q12W	4
Denosumab 180 mg Q4W	2

Time from study day 1 to first Skeletal Related Event (SRE), defined as >1 of the following: pathological bone fracture, spinal cord compression, surgery or radiation therapy to bone (including the use of radioisotopes). (NCT00104650)
Timeframe: Day 1, week 25

Time to Reduction of uNTX (Corrected by Creatinine) to <50nmol/mmol

Intervention	Participants (Number)
Bisphosphonate IV Q4W	6
Denosumab 180 mg Q12W	4
Denosumab 180 mg Q4W	2

Kaplan-Meier estimate of the median time from enrollment to the 1st occurrence of uNTx below 50 nmol BCE/mmol (corrected by creatinine) up to week 25. For participants whose uNTx does not go below 50 nM BCE/mM creatinine, the time is censored at time of last evaluation of uNTx by week 25. (NCT00104650)
Timeframe: Day 1, week 25

uNTx (Corrected by Creatinine) < 50 Nmol/mmol at Week 13

Intervention	Days (Median)
Bisphosphonate IV Q4W	65
Denosumab 180 mg Q12W	9
Denosumab 180 mg Q4W	10

Urinary N-telopeptide (uNTx) corrected by creatinine (uNTx/Cr) < 50 nmol/mmol at week 13. (NCT00104650)
Timeframe: 13 weeks

uNTx (Corrected by Creatinine) < 50 Nmol/mmol at Week 25

Intervention	Participants (Number)
Bisphosphonate IV Q4W	10
Denosumab 180 mg Q12W	21
Denosumab 180 mg Q4W	28

Urinary N-telopeptide (uNTX) corrected by creatinine < 50 nmol/mmol at week 25. (NCT00104650)
Timeframe: 25 weeks

Time to the First On-Study SRE (Non-inferiority)

Intervention	Participants (Number)
Bisphosphonate IV Q4W	13
Denosumab 180 mg Q12W	21
Denosumab 180 mg Q4W	23

Time to the first on-study skeletal-related event (SRE) analyzed for non-inferiority. Kaplan-Meier estimates of the median and its dispersion are reported. (NCT00321620)
Timeframe: Up to 40.5 months

Time to the First On-Study SRE (Superiority)

Intervention	Days (Median)
Zoledronic Acid	521.0
Denosumab	629.0

Time to the first on-study skeletal-related event (SRE), analyzed for superiority of denosumab. Kaplan-Meier estimates of the median and its dispersion are reported. (NCT00321620)
Timeframe: Up to 40.5 months

Time to the First-And-Subsequent On-Study SRE

Intervention	Days (Median)
Zoledronic Acid	521.0
Denosumab	629.0

"Time to the first-and-subsequent on-study skeletal-related event (SRE), analyzed for superiority of denosumab using multiple event analysis, the event must occur at least 21 days after the previous SRE.~This outcome measure utilizes multiple event times, was analyzed based on a proportional mean model, and is therefore more appropriately summarized by the cumulative mean number of events." (NCT00321620)
Timeframe: Up to 40.5 months

Numbers of SRE or Death Occurred Cumulatively

Intervention	Events (Number)
Zoledronic Acid	584
Denosumab	494

Number of participants experiencing a SRE(skeletal-related event) or death occurred, cumulative from each arm ( a daily oral dose of 30 mg risedronate, or placebo) (NCT00216060)
Timeframe: 36 months

Rate of Patients Archiving a PSA (Prostate Specific Antigen) Nadir < 0.2 ng/mL

Three- Year Survival Rate

Bone Turnover Marker Changes -- Urine Total Deoxypyridinoline (DPD)

Intervention	participants (Number)
Risedronate Arm	11
Placebo Arm	13

Intervention	percentage of participants (Number)
Risedronate Arm	50
Placebo Arm	29

Intervention	percentage of participants (Number)
Risedronate	72.5
Placebo	71.5

"Urine total DPD median in response to treatment on both study arms at week 24. compare median from baseline and week 24.~Deoxypyridinoline (DPD) is measured in hydrolyzed urine samples using high-performance liquid chromatography technique. After extraction of the cross-links and elimination of the urine impurities by a Bio-Rad SPE cartridge (Bio-Rad Laboratories, Hercules, CA), total DPD is eluted from reverse-phase high-performance liquid chromatography by ion pair chromatography with isocratic elution.~The compounds are detected as a result of their natural fluorescence with a fluorescence detector" (NCT00216060)
Timeframe: 24 weeks

Bone Turnover Marker Changes-- Serum BAP

Intervention	nmol/mmol creatinine (Median)
	week 24	baseline
Placebo Arm	12.62	10.12
Risedronate Arm	6.91	8.83

Serum BAP median changes between baseline and week 24. The Ostase assays are performed with an access immunoassay system, which is an assay of serum samples that provides a quantitative measurement of bone alkaline phosphatase (BAP). A mouse monoclonal antibody specific to BAP is added to a re-action vessel with paramagnetic particles coated with goat antimouse polyclonalantibody.Calibrators,controls,andsamplescontainingBAP are added to the coated particles and bind to the anti-BAP monoclonal antibody. After the formation of a solid phase/capture antibody/BAP complex, separation in a magnetic field and washing remove materials not bound to the solid phase. A chemiluminescent substrate, LumiPhos 530, is added to the reaction vessel, and light generated by the reaction is measured with a luminometer. The light production is directly proportional to the concentration of BAP in the sample. The amount of analyte in thesample is determined from a stored multipoint calibration curve (NCT00216060)
Timeframe: 24 week

Bone Turnover Marker Changes-- Serum Osteocalcin (OC)

Intervention	ng/mL (Median)
	24 week	baseline
Placebo Arm	13.16	19.50
Risedronate Arm	9.5	20.95

Serum Osteocalcin (OC) medians between baseline and 24 weeks areperformed with the Elecsys 2010 automated analyzer, which uses an electrochemiluminescence immunoassay technique for the in vitro quantitative determination of serum total osteocalcin in humanserum. The assay uses a sandwich test principle in which afirst biotinylated monoclonal antibody recognizing N-MID osteocalcin and a second monoclonal antibody against N-MID osteocalcin labeled with ruthenium are incubated with 20mL of serum. After a first incubation, streptavidin-coated microparticles are added for a second incubation, and the complex becomes bound to the solid phase by interaction of biotin and streptavidin.These microparticles are then magnetically captured onto the surface of an electrode. Application of a voltage on this electrode induces chemiluminescent emission, which is measured by a photomultiplierand compared with a calibration curve that is generated in aninstrument-specific manner by 2-point calibration. (NCT00216060)
Timeframe: 24 week

Bone Turnover Marker Changes-- Urine N-telopeptide (NTX) Median

Intervention	ug/L (Median)
	at 24 week	baseline
Placebo Arm	27.35	18.24
Risedronate Arm	11.88	20.08

"Urine N-telopeptide (NTX) median changes between baseline and week 24. The assays are performed with the NTx Reagent Pack kit from Ortho-Clinical Diagnostics (Ortho-Clinical Diagnostics/Johnson & Johnson, Amersham, UK), which is a kit designed for the quantitative determination of N-terminal telopeptide (NTx) in human urine on the automated Vitros Immunodiagnostic System ECi (Ortho-Clinical Diagnostics/Johnson & Johnson, Amersham, UK). A competitive immunoassay technique is used. This depends on competition between NTx present in the sample and a synthetic NTx peptide coated on the wells for binding by a horseradish peroxidase (HRP)-labeled antibody conjugate (mouse monoclonal anti-NTx). The conjugate is captured by the peptide coated on the wells; unbound materials are removed by washing.~The bound HRP conjugate is measured by a luminescent reaction." (NCT00216060)
Timeframe: 24 week

Article	Year
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
[Risk assessment in patients undergoing osseous antiresorptive therapy in dentistry. An update]. Schweizer Monatsschrift fur Zahnmedizin = Revue mensuelle suisse d'odonto-stomatologie = Rivista mensile svizzera di odontologia e stomatologia, 2013, Volume: 123, Issue:11 Topics: Aged; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Age	2013
[Therapeutic practice of bisphosphonate use and related pharmaceutical issues I]. Acta pharmaceutica Hungarica, 2016, Volume: 86, Issue:1 Topics: Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Neoplasms; Clodronic A	2016
Rare localizations of bone sarcoidosis: two case reports and review of the literature. Rheumatology international, 2011, Volume: 31, Issue:11 Topics: Alendronate; Bone Diseases; Bone Neoplasms; Diagnosis, Differential; Drug Therapy, Combination; Fema	2011
Denosumab: an update. Drugs of today (Barcelona, Spain : 1998), 2011, Volume: 47, Issue:8 Topics: Alendronate; Androgen Antagonists; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aromat	2011
Pathophysiology and medical treatment of pain in fibrous dysplasia of bone. Orphanet journal of rare diseases, 2012, May-24, Volume: 7 Suppl 1 Topics: Alendronate; Antibodies, Monoclonal, Humanized; Bone and Bones; Bone Neoplasms; Fibrous Dysplasia of	2012
Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease. Drug safety, 2006, Volume: 29, Issue:12 Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Etidronic Ac	2006
[Osteonecrosis of the jaw developing during bisphosphonate treatment]. Magyar onkologia, 2008, Volume: 52, Issue:1 Topics: Alendronate; Anti-Infective Agents; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodelin	2008
Use of bisphosphonates in cancer patients. Cancer treatment reviews, 1996, Volume: 22, Issue:4 Topics: Alendronate; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clodronic Acid; Diphosphonates; Etid	1996
Bisphosphonates in prostate carcinoma. Cancer, 1997, Oct-15, Volume: 80, Issue:8 Suppl Topics: Alendronate; Biomarkers; Bone Diseases; Bone Neoplasms; Bone Resorption; Clinical Trials as Topic; C	1997
Oral bisphosphonates: A review of clinical use in patients with bone metastases. Cancer, 2000, Jan-01, Volume: 88, Issue:1 Topics: Alendronate; Biological Availability; Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasm	2000
Bisphosphonates: an overview with special reference to alendronate. Annals of clinical biochemistry, 2001, Volume: 38, Issue:Pt 6 Topics: Alendronate; Bone Density; Bone Neoplasms; Bone Resorption; Calcium; Clinical Trials as Topic; Dipho	2001
Hypercalcemia and bone metastases in breast cancer. Current opinion in oncology, 1990, Volume: 2, Issue:6 Topics: Alendronate; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Etidronic Acid; Hyper	1990

Article	Year
Effect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic acid. JAMA internal medicine, 2014, Volume: 174, Issue:10 Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Bone Neoplasms; Breast Neopl	2014
A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases. The Journal of urology, 2005, Volume: 173, Issue:3 Topics: Aged; Alendronate; Bone Neoplasms; Drug Therapy, Combination; Humans; Ketoconazole; Male; Middle Age	2005
Comparison of a rapid (2-h) versus a slow (24-h) infusion of alendronate in the treatment of hypercalcemia of malignancy. Bone and mineral, 1992, Volume: 18, Issue:3 Topics: Aged; Aged, 80 and over; Alendronate; Bone Neoplasms; Bone Resorption; Calcium; Diphosphonates; Doub	1992
Hypercalcemia and bone metastases in breast cancer. Current opinion in oncology, 1990, Volume: 2, Issue:6 Topics: Alendronate; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Etidronic Acid; Hyper	1990
Effects of a new aminodiphosphonate (aminohydroxybutylidene diphosphonate) in patients with osteolytic lesions from metastases and myelomatosis. Comparison with dichloromethylene diphosphonate. Archives of internal medicine, 1987, Volume: 147, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Alendronate; Antineoplastic Combined Chemotherapy Protocols; Bone Ne	1987

Article	Year
Enhancement of Cancer Chemotherapeutic Efficacy via Bone-Targeted Drug Delivery Carrier in Bone Metastases. Drug design, development and therapy, 2021, Volume: 15 Topics: Alendronate; Animals; Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Doxorubicin; Drug Car	2021
Development of local injectable, bone-targeting nanocarriers of triptolide for treatment of bone-only metastasis. International journal of pharmaceutics, 2022, Sep-25, Volume: 625 Topics: Alendronate; Bone Neoplasms; Diterpenes; Docetaxel; Epoxy Compounds; Humans; Phenanthrenes	2022
Acidity-Triggered Transformable Polypeptide Self-Assembly to Initiate Tumor-Specific Biomineralization. Advanced materials (Deerfield Beach, Fla.), 2023, Volume: 35, Issue:15 Topics: Alendronate; Animals; Biomineralization; Bone Neoplasms; Cell Line, Tumor; Glutamic Acid; Mice; Nano	2023
Bone-Targeted Dual Functional Lipid-coated Drug Delivery System for Osteosarcoma Therapy. Pharmaceutical research, 2023, Volume: 40, Issue:1 Topics: Adolescent; Alendronate; Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Child; Cisplatin;	2023
Bone-Targeted Dual Functional Lipid-coated Drug Delivery System for Osteosarcoma Therapy. Pharmaceutical research, 2023, Volume: 40, Issue:1 Topics: Adolescent; Alendronate; Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Child; Cisplatin;	2023
Bone-Targeted Dual Functional Lipid-coated Drug Delivery System for Osteosarcoma Therapy. Pharmaceutical research, 2023, Volume: 40, Issue:1 Topics: Adolescent; Alendronate; Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Child; Cisplatin;	2023
Bone-Targeted Dual Functional Lipid-coated Drug Delivery System for Osteosarcoma Therapy. Pharmaceutical research, 2023, Volume: 40, Issue:1 Topics: Adolescent; Alendronate; Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Child; Cisplatin;	2023
Bone-Targeted Dual Functional Lipid-coated Drug Delivery System for Osteosarcoma Therapy. Pharmaceutical research, 2023, Volume: 40, Issue:1 Topics: Adolescent; Alendronate; Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Child; Cisplatin;	2023
Bone-Targeted Dual Functional Lipid-coated Drug Delivery System for Osteosarcoma Therapy. Pharmaceutical research, 2023, Volume: 40, Issue:1 Topics: Adolescent; Alendronate; Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Child; Cisplatin;	2023
Bone-Targeted Dual Functional Lipid-coated Drug Delivery System for Osteosarcoma Therapy. Pharmaceutical research, 2023, Volume: 40, Issue:1 Topics: Adolescent; Alendronate; Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Child; Cisplatin;	2023
Bone-Targeted Dual Functional Lipid-coated Drug Delivery System for Osteosarcoma Therapy. Pharmaceutical research, 2023, Volume: 40, Issue:1 Topics: Adolescent; Alendronate; Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Child; Cisplatin;	2023
Bone-Targeted Dual Functional Lipid-coated Drug Delivery System for Osteosarcoma Therapy. Pharmaceutical research, 2023, Volume: 40, Issue:1 Topics: Adolescent; Alendronate; Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Child; Cisplatin;	2023
Alendronate conjugate for targeted delivery to bone-forming prostate cancer. Talanta, 2023, May-01, Volume: 256 Topics: Alendronate; Animals; Bone Neoplasms; Cell Line, Tumor; Endothelial Cells; Humans; Hydroxyapatites;	2023
Dual targeting curcumin loaded alendronate-hyaluronan- octadecanoic acid micelles for improving osteosarcoma therapy. International journal of nanomedicine, 2019, Volume: 14 Topics: Alendronate; Animals; Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Curcumin; Drug Carrie	2019
Mesoporous bioactive glasses for the combined application of osteosarcoma treatment and bone regeneration. Materials science & engineering. C, Materials for biological applications, 2019, Volume: 104 Topics: Alendronate; Bone Neoplasms; Bone Regeneration; Cell Line; Cell Proliferation; Glass; Humans; Osteob	2019
Potentiating bisphosphonate-based coordination complexes to treat osteolytic metastases. Journal of materials chemistry. B, 2020, 03-11, Volume: 8, Issue:10 Topics: Alendronate; Antineoplastic Agents; Bone Neoplasms; Cell Proliferation; Coordination Complexes; Diph	2020
Alendronate/folic acid-decorated polymeric nanoparticles for hierarchically targetable chemotherapy against bone metastatic breast cancer. Journal of materials chemistry. B, 2020, 05-06, Volume: 8, Issue:17 Topics: Alendronate; Animals; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Cell Line	2020
Bone-targeted PAMAM nanoparticle to treat bone metastases of lung cancer. Nanomedicine (London, England), 2020, Volume: 15, Issue:9 Topics: Alendronate; Animals; Antineoplastic Agents; Bone Neoplasms; Docetaxel; Drug Delivery Systems; Lung	2020
Bisphosphonate-functionalized micelles for targeted delivery of curcumin to metastatic bone cancer. Pharmaceutical development and technology, 2020, Volume: 25, Issue:9 Topics: Alendronate; Antineoplastic Agents; Bone Neoplasms; Curcumin; Diphosphonates; Drug Carriers; Drug De	2020
Low molecular weight heparin modified bone targeting liposomes for orthotopic osteosarcoma and breast cancer bone metastatic tumors. International journal of biological macromolecules, 2020, Dec-01, Volume: 164 Topics: Alendronate; Animals; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Prolif	2020
Bisphosphonate-functionalized coordination polymer nanoparticles for the treatment of bone metastatic breast cancer. Journal of controlled release : official journal of the Controlled Release Society, 2017, Oct-28, Volume: 264 Topics: Alendronate; Animals; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cel	2017
Cytotoxic and inflammatory effects of alendronate and zolendronate on human osteoblasts, gingival fibroblasts and osteosarcoma cells. Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery, 2018, Volume: 46, Issue:4 Topics: Alendronate; Apoptosis; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytokin	2018
In Vivo Evaluation of Reduction-Responsive Alendronate-Hyaluronan-Curcumin Polymer-Drug Conjugates for Targeted Therapy of Bone Metastatic Breast Cancer. Molecular pharmaceutics, 2018, 07-02, Volume: 15, Issue:7 Topics: Alendronate; Animals; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cur	2018
Multifunctional melanin-like nanoparticles for bone-targeted chemo-photothermal therapy of malignant bone tumors and osteolysis. Biomaterials, 2018, Volume: 183 Topics: Alendronate; Animals; Antineoplastic Agents; Bone and Bones; Bone Neoplasms; Cells, Cultured; Combin	2018
Bortezomib-catechol conjugated prodrug micelles: combining bone targeting and aryl boronate-based pH-responsive drug release for cancer bone-metastasis therapy. Nanoscale, 2018, Oct-04, Volume: 10, Issue:38 Topics: Alendronate; Animals; Antineoplastic Agents; Bone Neoplasms; Bortezomib; Breast Neoplasms; Catechols	2018
Engineering of Bone- and CD44-Dual-Targeting Redox-Sensitive Liposomes for the Treatment of Orthotopic Osteosarcoma. ACS applied materials & interfaces, 2019, Feb-20, Volume: 11, Issue:7 Topics: Alendronate; Animals; Bone Neoplasms; Cell Line, Tumor; Cell Survival; Female; Humans; Hyaluronan Re	2019
Alendronate-Modified Polymeric Micelles for the Treatment of Breast Cancer Bone Metastasis. Molecular pharmaceutics, 2019, 07-01, Volume: 16, Issue:7 Topics: Alendronate; Animals; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breas	2019
Incidence of osteonecrosis of the jaw by the use of osteoclast inhibitors in patients with bone metastases: a retrospective cohort study. Cirugia y cirujanos, 2019, Volume: 87, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bon	2019
Poly(ethylene glycol)-paclitaxel-alendronate self-assembled micelles for the targeted treatment of breast cancer bone metastases. Biomaterials, 2013, Volume: 34, Issue:15 Topics: Alendronate; Animals; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Breast Neoplasms; Cell Line,	2013
Bisphosphonate-related osteonecrosis of jaw (BRONJ) in Japanese population: a case series of 13 patients at our clinic. The Bulletin of Tokyo Dental College, 2013, Volume: 54, Issue:2 Topics: Administration, Oral; Adrenal Cortex Hormones; Aged; Aged, 80 and over; Alendronate; Anti-Bacterial	2013
Osteotropic therapy via targeted layer-by-layer nanoparticles. Advanced healthcare materials, 2014, Volume: 3, Issue:6 Topics: Acrylic Resins; Alendronate; Animals; Bone Density Conservation Agents; Bone Neoplasms; Cell Line, T	2014
Differential impact of adenosine nucleotides released by osteocytes on breast cancer growth and bone metastasis. Oncogene, 2015, Apr-02, Volume: 34, Issue:14 Topics: Adenosine; Adenosine Triphosphate; Alendronate; Animals; Apyrase; Bone Density Conservation Agents;	2015
Bisphosphonate release profiles from magnetite microspheres. Journal of biomaterials applications, 2014, Volume: 29, Issue:4 Topics: Alendronate; Biocompatible Materials; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonat	2014
Engineered nanomedicine for myeloma and bone microenvironment targeting. Proceedings of the National Academy of Sciences of the United States of America, 2014, Jul-15, Volume: 111, Issue:28 Topics: Alendronate; Animals; Antineoplastic Agents; Bone Neoplasms; Boronic Acids; Bortezomib; Cell Line, T	2014
In vitro and in vivo toxicity of 5-FdU-alendronate, a novel cytotoxic bone-seeking duplex drug against bone metastasis. Investigational new drugs, 2015, Volume: 33, Issue:4 Topics: Alendronate; Animals; Antimetabolites, Antineoplastic; Bone Density Conservation Agents; Bone Neopla	2015
Doxorubicin-poly (ethylene glycol)-alendronate self-assembled micelles for targeted therapy of bone metastatic cancer. Scientific reports, 2015, Sep-30, Volume: 5 Topics: Alendronate; Animals; Antibiotics, Antineoplastic; Bone Density Conservation Agents; Bone Neoplasms;	2015
Development of Alendronate-conjugated Poly (lactic-co-glycolic acid)-Dextran Nanoparticles for Active Targeting of Cisplatin in Osteosarcoma. Scientific reports, 2015, Dec-01, Volume: 5 Topics: Alendronate; Animals; Bone Neoplasms; Cell Line, Tumor; Cisplatin; Dextrans; Drug Carriers; Humans;	2015
[Bisphosphonate use and related pharmaceutical issues II]. Acta pharmaceutica Hungarica, 2016, Volume: 86, Issue:1 Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Bone Neoplasms; Clodronic Acid;	2016
Pharmacologically Inactive Bisphosphonates as an Alternative Strategy for Targeting Osteoclasts: In Vivo Assessment of 5-Fluorodeoxyuridine-Alendronate in a Preclinical Model of Breast Cancer Bone Metastases. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2017, Volume: 32, Issue:3 Topics: Alendronate; Animals; Apoptosis; Biomarkers, Tumor; Bone Neoplasms; Bone Resorption; Caspases; Cell	2017
Engineered Nanomedicine with Alendronic Acid Corona Improves Targeting to Osteosarcoma. Scientific reports, 2016, 11-08, Volume: 6 Topics: Alendronate; Biocompatible Materials; Bone Density Conservation Agents; Bone Neoplasms; Calcium; Cel	2016
Calcium phosphate nanoparticles functionalized with alendronate-conjugated polyethylene glycol (PEG) for the treatment of bone metastasis. International journal of pharmaceutics, 2017, Jan-10, Volume: 516, Issue:1-2 Topics: Alendronate; Animals; Antimetabolites, Antineoplastic; Bone Neoplasms; Calcium Phosphates; Cell Line	2017
Bisphosphonate-related osteonecrosis of the jaws--report of 2 cases and strategies on prevention and management. Quintessence international (Berlin, Germany : 1985), 2008, Volume: 39, Issue:3 Topics: Aged; Alendronate; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans;	2008
Targeting bone metastases with a bispecific anticancer and antiangiogenic polymer-alendronate-taxane conjugate. Angewandte Chemie (International ed. in English), 2009, Volume: 48, Issue:16 Topics: Acrylamides; Alendronate; Angiogenesis Inhibitors; Antineoplastic Agents; Bone Neoplasms; Bridged-Ri	2009
Alendronate inhibits growth of high-grade chondrosarcoma cells. Anticancer research, 2009, Volume: 29, Issue:6 Topics: Alendronate; Blotting, Western; Bone Density Conservation Agents; Bone Neoplasms; Cell Adhesion; Cel	2009
188Re(CO)3-dipicolylamine-alendronate: a new bisphosphonate conjugate for the radiotherapy of bone metastases. Bioconjugate chemistry, 2010, May-19, Volume: 21, Issue:5 Topics: Alendronate; Animals; Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Mice; M	2010
How patients' lack of knowledge about oral bisphosphonates can interfere with medical and dental care. Journal of the American Dental Association (1939), 2010, Volume: 141, Issue:5 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conser	2010
Bone-targeted doxorubicin-loaded nanoparticles as a tool for the treatment of skeletal metastases. Current cancer drug targets, 2010, Volume: 10, Issue:7 Topics: Acid Phosphatase; Alendronate; Animals; Antineoplastic Agents; Biological Transport; Bone Density Co	2010
[Jaw osteonecrosis induced by oral biphosphonates: 12 cases]. Revue de stomatologie et de chirurgie maxillo-faciale, 2010, Volume: 111, Issue:4 Topics: Administration, Oral; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Alendronate; Autoimmu	2010
Enhanced anti-tumor activity and safety profile of targeted nano-scaled HPMA copolymer-alendronate-TNP-470 conjugate in the treatment of bone malignances. Biomaterials, 2011, Volume: 32, Issue:19 Topics: Acrylamides; Alendronate; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Body Weight; Bone	2011
Antiangiogenic antitumor activity of HPMA copolymer-paclitaxel-alendronate conjugate on breast cancer bone metastasis mouse model. Molecular pharmaceutics, 2011, Aug-01, Volume: 8, Issue:4 Topics: Acrylamides; Alendronate; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Bone Neoplasms; B	2011
Dendritic poly(ethylene glycol) bearing paclitaxel and alendronate for targeting bone neoplasms. Molecular pharmaceutics, 2011, Aug-01, Volume: 8, Issue:4 Topics: Alendronate; Animals; Bone Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dendrimer	2011
Low concentrations of alendronate increase the local invasive potential of osteoblastic sarcoma cell lines via connexin 43 activation. Pathology, research and practice, 2011, Jul-15, Volume: 207, Issue:7 Topics: Alendronate; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; C	2011
The effect of poly(d,l-lactide-co-glycolide)-alendronate conjugate nanoparticles on human osteoclast precursors. Journal of biomaterials science. Polymer edition, 2012, Volume: 23, Issue:10 Topics: Actins; Alendronate; Apoptosis; Bone Density Conservation Agents; Bone Neoplasms; Cells, Cultured; C	2012
Alendronate coated poly-lactic-co-glycolic acid (PLGA) nanoparticles for active targeting of metastatic breast cancer. Biomaterials, 2012, Volume: 33, Issue:29 Topics: Alendronate; Animals; Antineoplastic Agents; Bone and Bones; Bone Neoplasms; Boronic Acids; Bortezom	2012
Cytostatic activity of a 5-fluoro-2'-deoxyuridine-alendronate conjugate against gastric adenocarcinoma and non-malignant intestinal and fibroblast cell lines. Anticancer research, 2012, Volume: 32, Issue:10 Topics: Adenocarcinoma; Alendronate; Bone Density Conservation Agents; Bone Neoplasms; Cell Line; Cell Line,	2012
Osteosarcoma diagnostic delay associated with alendronate-induced pain relief. Journal of surgical orthopaedic advances, 2012,Fall, Volume: 21, Issue:3 Topics: Adult; Alendronate; Bone Density Conservation Agents; Bone Neoplasms; Diagnostic Errors; Humans; Mal	2012
Bisphosphonates induce apoptosis of stromal tumor cells in giant cell tumor of bone. Calcified tissue international, 2004, Volume: 75, Issue:1 Topics: Alendronate; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Diphosphonates; DNA Fragmentation; DN	2004
Bone cancer pain: the effects of the bisphosphonate alendronate on pain, skeletal remodeling, tumor growth and tumor necrosis. Pain, 2004, Volume: 111, Issue:1-2 Topics: Activating Transcription Factor 3; Alendronate; Animals; Behavior, Animal; Biomarkers, Tumor; Bone N	2004
Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2005, Volume: 63, Issue:11 Topics: Abscess; Alendronate; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breas	2005
Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma and breast cancer. Acta haematologica, 2007, Volume: 117, Issue:3 Topics: Alendronate; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Fem	2007
Bone necrosis of the jaws associated with bisphosphonate treatment: a report of twenty-nine cases. Acta bio-medica : Atenei Parmensis, 2006, Volume: 77, Issue:2 Topics: Aged; Aged, 80 and over; Alendronate; Anti-Bacterial Agents; Antifungal Agents; Bone Density Conserv	2006
Bisphosphonates: are they standard of care for the treatment of breast cancer? British journal of cancer, 2007, Jun-18, Volume: 96, Issue:12 Topics: Alendronate; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Fem	2007
Alendronate inhibits cell invasion and MMP-2 secretion in human chondrosarcoma cell line. Acta pharmacologica Sinica, 2007, Volume: 28, Issue:8 Topics: Alendronate; Bone Neoplasms; Cell Line, Tumor; Cell Movement; Cell Survival; Chondrosarcoma; Humans;	2007
Oral bisphosphonate associated osteonecrosis of the jaws: three case reports. British dental journal, 2007, Jul-28, Volume: 203, Issue:2 Topics: Administration, Oral; Aged; Alendronate; Anti-Bacterial Agents; Bone Density Conservation Agents; Bo	2007
The bisphosphonate dilemma. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1995, Volume: 36, Issue:4 Topics: Alendronate; Bone and Bones; Bone Neoplasms; Clodronic Acid; Diphosphonates; False Negative Reaction	1995
Effects of alendronate and taxol on PC-3 ML cell bone metastases in SCID mice. Invasion & metastasis, 1996, Volume: 16, Issue:3 Topics: Alendronate; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protoc	1996
Alendronate blocks TGF-beta1 stimulated collagen 1 degradation by human prostate PC-3 ML cells. Clinical & experimental metastasis, 1998, Volume: 16, Issue:4 Topics: Alendronate; Antineoplastic Agents; Bone Neoplasms; Collagen; Gelatinases; Humans; Hydroxyproline; M	1998
[A study of the safety of rapid infusion of alendronate]. Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:3 Topics: Alendronate; Blood Urea Nitrogen; Bone Neoplasms; Breast Neoplasms; Calcium; Drug Administration Sch	1999
Alendronate blocks metalloproteinase secretion and bone collagen I release by PC-3 ML cells in SCID mice. Clinical & experimental metastasis, 1998, Volume: 16, Issue:8 Topics: Alendronate; Animals; Bone Neoplasms; Collagen; Collagenases; Enzyme-Linked Immunosorbent Assay; Gel	1998
Synthesis and preclinical pharmacology of 2-(2-aminopyrimidinio) ethylidene-1,1-bisphosphonic acid betaine (ISA-13-1)-a novel bisphosphonate. Pharmaceutical research, 1999, Volume: 16, Issue:9 Topics: Administration, Oral; Alendronate; Animals; Antineoplastic Agents; Betaine; Bone Diseases; Bone Neop	1999
[Effective alendronate therapy against a bone metastasis occurring during docetaxel therapy for breast cancer--a case report]. Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:10 Topics: Aged; Alendronate; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Docetaxel; F	1999
[Pain relief with alendronate therapy in a breast cancer patient with bone metastasis]. Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:4 Topics: Aged; Alendronate; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Bone Neoplasms; Breast Ne	2000
Use of the bisphosphonate drug alendronate for palliative management of osteosarcoma in two dogs. The Veterinary record, 2000, Jul-29, Volume: 147, Issue:5 Topics: Alendronate; Animals; Bone Neoplasms; Bone Remodeling; Dog Diseases; Dogs; Male; Osteolysis; Osteosa	2000
Effects of alendronate on bone metastases and hypercalcemia after surgery for hepatocellular carcinoma. Japanese journal of clinical oncology, 2000, Volume: 30, Issue:9 Topics: Aged; Alendronate; Bone Neoplasms; Carcinoma, Hepatocellular; Female; Humans; Hypercalcemia; Liver N	2000
Labelling of Re-ABP with 188Re for bone pain palliation. Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine, 2001, Volume: 54, Issue:3 Topics: Alendronate; Animals; Bone Neoplasms; Humans; Indicators and Reagents; Palliative Care; Radioisotope	2001
Alendronate does not interfere with 99mTc-methylene diphosphonate bone scanning. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2001, Volume: 42, Issue:9 Topics: Aged; Alendronate; Bone Neoplasms; Humans; Male; Middle Aged; Prospective Studies; Prostatic Neoplas	2001
Tc99m-sestamibi uptake in osteitis fibrosa cystica simulating metastatic bone disease. The Journal of clinical endocrinology and metabolism, 2001, Volume: 86, Issue:11 Topics: Adult; Alendronate; Biomarkers; Bone Neoplasms; Diagnosis, Differential; Hormone Replacement Therapy	2001
Pharmacokinetic and pharmacodynamic evaluation of intermittent versus continuous alendronate administration in rats. Journal of pharmaceutical sciences, 2002, Volume: 91, Issue:2 Topics: Alendronate; Animals; Bone Neoplasms; Bone Resorption; Calcium; Carcinoma 256, Walker; Drug Administ	2002
Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway. Cancer research, 2002, May-01, Volume: 62, Issue:9 Topics: Alendronate; Antimetabolites; Bone Neoplasms; Cell Movement; Clodronic Acid; Dose-Response Relations	2002
Response of MBT-2 bladder carcinoma-induced osteolysis to various agents. Cancer, 1992, May-01, Volume: 69, Issue:9 Topics: Alendronate; Animals; Bone Neoplasms; Bone Resorption; Calcitonin; Cyclosporine; Diphosphonates; Fem	1992

alendronate and Bone Cancer

Research Excerpts

Research

Studies (89)

Authors

Clinical Trials (11)

Trial Overview

Trial Outcomes

Overall Survival

Progression-free Survival

Time to First Skeletal Related Event

Duration of Maintaining uNTX (Corrected by Creatinine) < 50nmol/mmol

Hypercalcemia

Percent Change of Serum CTX From Baseline to Week 25

Percent Change of uNTx (Corrected by Creatinne) From Baseline to Week 25

Skeletal Related Events

Time to First Skeletal Related Event

Time to Reduction of uNTX (Corrected by Creatinine) to <50nmol/mmol

uNTx (Corrected by Creatinine) < 50 Nmol/mmol at Week 13

uNTx (Corrected by Creatinine) < 50 Nmol/mmol at Week 25

Time to the First On-Study SRE (Non-inferiority)

Time to the First On-Study SRE (Superiority)

Time to the First-And-Subsequent On-Study SRE

Numbers of SRE or Death Occurred Cumulatively

Rate of Patients Archiving a PSA (Prostate Specific Antigen) Nadir < 0.2 ng/mL

Three- Year Survival Rate

Bone Turnover Marker Changes -- Urine Total Deoxypyridinoline (DPD)

Bone Turnover Marker Changes-- Serum BAP

Bone Turnover Marker Changes-- Serum Osteocalcin (OC)

Bone Turnover Marker Changes-- Urine N-telopeptide (NTX) Median

Reviews

Trials

Other Studies